KTTA · Pasithea Therapeutics Corp
United States · RS rating 12 · As of 2026-10-14
| Price | 0.41 USD |
|---|---|
| 1-day change | -3.4% |
| RS rating (overall / 1M / 3M / 12M) | 12 / 13 / 31 / 16 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 11 / 29 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -33.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +72.2% |
| Market cap (USD) | $17.2M |